Baxter’s Relaunch Of Recalled Infusion Pump Will Add $75 Mil. In ’08 Sales
This article was originally published in The Gray Sheet
Executive Summary
Baxter expects a mid-year U.S. relaunch of previously recalled Colleague infusion pumps to generate $75 million in sales in 2008
You may also be interested in...
Earnings Calls In Brief
J&J sees limited impact from financial crisis: Johnson & Johnson Chief Financial Officer Dominic Caruso says only "small pockets" of J&J's business were impacted by the global economic crisis in the third quarter. During the firm's Oct. 14 earnings call, Caruso cited certain products for elective procedures in sports medicine and women's health, in addition to some consumer health products. "They are still growing, but just subsiding a little bit in growth," he explained. J&J's Ethicon and Ethicon Endo-Surgery surgical business units reported revenue growth of 8.6% and 13%, respectively, over the prior-year period. The firm's DePuy orthopedics business reported 10% growth. The only declining device unit was Cordis, which dropped 6.6% due to struggling drug-eluting stent sales amidst increasing competition in the market. Overall, J&J's device business revenue grew 8.8% to $5.7 billion in the third quarter
Earnings Calls In Brief
J&J sees limited impact from financial crisis: Johnson & Johnson Chief Financial Officer Dominic Caruso says only "small pockets" of J&J's business were impacted by the global economic crisis in the third quarter. During the firm's Oct. 14 earnings call, Caruso cited certain products for elective procedures in sports medicine and women's health, in addition to some consumer health products. "They are still growing, but just subsiding a little bit in growth," he explained. J&J's Ethicon and Ethicon Endo-Surgery surgical business units reported revenue growth of 8.6% and 13%, respectively, over the prior-year period. The firm's DePuy orthopedics business reported 10% growth. The only declining device unit was Cordis, which dropped 6.6% due to struggling drug-eluting stent sales amidst increasing competition in the market. Overall, J&J's device business revenue grew 8.8% to $5.7 billion in the third quarter
Hospital-Acquired Infections Create Market For Novel Tests And Interventions
A stream of new products designed to prevent hospital-acquired infections are hitting the market as state and federal legislators and the public are pressuring hospitals and industry to reduce infection risks